MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram

Important Resources for the MS community are found on the left side of this blog.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Monday, July 7, 2008

Higher dose of MS drug no more efficient - says Teva

Reuters- Yahoo News

Mon Jul 7, 2:47 AM ET


(Reuters) - Teva Pharmaceutical Industries Ltd said data from a late-stage trial showed an increased dose of its multiple sclerosis drug, glatiramer acetate (GA), was not more efficient than an approved lower-dose version of the drug.

Teva was studying the efficacy, safety and tolerability of a 40mg version of GA compared with an approved 20mg version that is sold under the brand name Copaxone.

But the higher dose maintained the favorable safety and tolerability profile of Copaxone, the company, which is evaluating the use of GA for additional indications, said in a statement on Monday.

(Reporting by Pratish Narayanan in Bangalore; Editing by David Holmes)




===========================================

If you want to leave a comment to this article, you need to return-to
(or remain on) - this page

============================================

No comments: